Pharmacological treatment of COVID-19 : an opinion paper
©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)..
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 35(2022), 2 vom: 24. Apr., Seite 115-130 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
García-Lledó, A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/158.2021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334307066 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334307066 | ||
| 003 | DE-627 | ||
| 005 | 20231225223430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/158.2021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM334307066 | ||
| 035 | |a (NLM)34894208 | ||
| 035 | |a (PII)bouza11dec2021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a García-Lledó, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological treatment of COVID-19 |b an opinion paper |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). | ||
| 520 | |a The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AZD7442 | |
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a Anakinra | |
| 650 | 4 | |a Azithromycin | |
| 650 | 4 | |a BRII-196 | |
| 650 | 4 | |a BRII-198 | |
| 650 | 4 | |a Banlanivimab | |
| 650 | 4 | |a Baricitinib | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Canakinumab | |
| 650 | 4 | |a Casirivimab | |
| 650 | 4 | |a Certolizumab | |
| 650 | 4 | |a Ciganilmab | |
| 650 | 4 | |a Colchicine | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Etanercept | |
| 650 | 4 | |a Etesevimab | |
| 650 | 4 | |a Evusheld | |
| 650 | 4 | |a Favipiravir | |
| 650 | 4 | |a Fluvoxamine | |
| 650 | 4 | |a Golimumab | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Imdevinab | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Itolizumab | |
| 650 | 4 | |a Ivermectin | |
| 650 | 4 | |a Lemilumab | |
| 650 | 4 | |a Lopinavir/Ritonavir | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a Molnupiravir | |
| 650 | 4 | |a PF-07321332 | |
| 650 | 4 | |a Paxlovid | |
| 650 | 4 | |a Ravulizumab | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a Ruxolitinib | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sarilumab | |
| 650 | 4 | |a Sotrovimab | |
| 650 | 4 | |a Tixagevimab | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a Tofacitinib | |
| 650 | 4 | |a Vitamin D | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Gómez-Pavón, J |e verfasserin |4 aut | |
| 700 | 1 | |a González Del Castillo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Sampelayo, T |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Delgado, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Sánchez, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Sellés, M |e verfasserin |4 aut | |
| 700 | 1 | |a Molero García, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Guillén, S |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Artalejo, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Galiana, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón, R |e verfasserin |4 aut | |
| 700 | 1 | |a De Lucas Ramos, P |e verfasserin |4 aut | |
| 700 | 1 | |a García-Botella, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bouza, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 35(2022), 2 vom: 24. Apr., Seite 115-130 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:2 |g day:24 |g month:04 |g pages:115-130 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/158.2021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 2 |b 24 |c 04 |h 115-130 | ||